Match!
Rachel Simpson
Newcastle University
CD3Peripheral blood mononuclear cellCytokineFibrosisMedicine
2Publications
1H-index
34Citations
What is this?
Publications 6
Newest
#1Rachel SimpsonH-Index: 1
#2Stephanie Ka Ching Lau (U of O: University of Ottawa)H-Index: 1
Last. Jason Kihyuk LeeH-Index: 1
view all 3 authors...
IgG4-related disease (IgG4-RD) is a rare fibroinflammatory, multisystemic condition with a relapsing-remitting progression.1 The level of serum IgG4 correlates with inflammatory activity and organ involvement.1 Glucocorticoids are first line for IgG4-RD, but there are numerous adverse effects with chronic use.2 Dupilumab is a monoclonal antibody that acts on the interleukin 4 (IL-4) receptor alpha, shared by the IL-4 and IL-13 receptors.1 IL-4 causes isotype switching from IgM to IgG4 and IL-13 ...
7 CitationsSource
We thank Ebbo et al for their interest in our case report1 and for providing their case of a patient with IgG4-related disease (IgG4-RD) whom they have also treated with dupilumab.2 Notably, Ebbo et al reported variability in the response to dupilumab compared with our patient. Our patient did have different clinical manifestations than that of Ebbo et al ’s patient, as our patient had profound retroperitoneal and genitourinary fibrosis along with atopic dermatitis, asthma, allergic rhinoconjunc...
Source
We thank Della-Torre et al for their interest in our paper and for providing their thoughts through correspondence.1 2 As they have summarised, our case described a patient whom was prescribed a 40 mg daily dose of prednisone to treat his IgG4-related disease (IgG4-RD); however, the patient declined to pursue additional adjunct immunosuppressants due to the concern of adverse effects.1 To hopefully mitigate such concerns and control his disease, we proposed that dupilumab, a monoclonal anti-inte...
1 CitationsSource
We thank Akiyama et al , for their kind words regarding our manuscript.1 We agree that IgG4-related disease (IgG4-RD) relapse frequently occurs in patients tapering glucocorticoids, and we wanted to offer a novel solution to our patient to potentially mitigate or all together avoid this. As communicated in our previous correspondence response2 it has actually come to our attention post-publication (December 29th, 2019) that the patient noted in our report never took a dose of prednisone that was...
Source
#1Thomas Hügle (Newcastle University)H-Index: 22
#2Steven O’Reilly (Newcastle University)H-Index: 19
Last. Jacob M. van Laar (Newcastle University)H-Index: 50
view all 8 authors...
Objective The role of tumor necrosis factor (TNF) in systemic sclerosis (SSc) remains controversial. The present study was undertaken to investigate the influence of TNF receptor (TNFR)–costimulated lymphocytes on collagen expression in fibroblasts. Methods TNFR expression on mononuclear cells from the dermis and blood of SSc patients was assessed by flow cytometry. Peripheral blood CD3+ lymphocytes were activated with CD3/CD28 beads and costimulated with TNFR-selective variants. Expression of i...
34 CitationsSource
#1Thomas Hügle (Newcastle University)H-Index: 22
#2Anja Krippner-Heidenreich (Newcastle University)H-Index: 16
Last. Jacob M. van Laar (Newcastle University)H-Index: 50
view all 9 authors...
Background and objectives Systemic sclerosis (SSc) is an auto-inflammatory multisystem disease leading to fibrosis of the skin and inner organs. T lymphocytes are key effector cells in the affected tissue. The role of lymphocytes in the transition from inflammation to fibrosis is unclear. Previous data suggested a possible pro-fibrotic effect of tumour necrosis factor–receptor (TNF-R) 2. Materials and methods Skin punch biopsies from affected skin of 12 SSc patients (six limited, six diffuse) we...
Source
1